See more : Médica Sur, S.A.B. de C.V. (MEDICAB.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Kenvue Inc. (KVUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kenvue Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- China Conch Venture Holdings Limited (0586.HK) Income Statement Analysis – Financial Results
- Farmers Edge Inc. (FMEGF) Income Statement Analysis – Financial Results
- Baguio Green Group Limited (1397.HK) Income Statement Analysis – Financial Results
- Kri-Kri Milk Industry S.A. (KRI.AT) Income Statement Analysis – Financial Results
- Air Lease Corporation (AL) Income Statement Analysis – Financial Results
Kenvue Inc. (KVUE)
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 15.44B | 14.95B | 15.05B | 14.47B | 14.32B |
Cost of Revenue | 6.80B | 6.67B | 6.64B | 6.62B | 6.66B |
Gross Profit | 8.64B | 8.29B | 8.42B | 7.85B | 7.66B |
Gross Profit Ratio | 55.96% | 55.42% | 55.93% | 54.25% | 53.49% |
Research & Development | 399.00M | 375.00M | 355.00M | 320.00M | 391.00M |
General & Administrative | 4.33B | 4.28B | 4.02B | 3.73B | 3.94B |
Selling & Marketing | 1.35B | 1.36B | 1.46B | 1.23B | 1.26B |
SG&A | 5.68B | 5.63B | 5.48B | 4.96B | 5.20B |
Other Expenses | 50.00M | 4.00M | 25.00M | 3.00M | 59.00M |
Operating Expenses | 6.13B | 5.62B | 5.41B | 4.86B | 5.26B |
Cost & Expenses | 12.93B | 12.28B | 12.04B | 11.48B | 11.93B |
Interest Income | 108.00M | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 358.00M | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 627.00M | 644.00M | 731.00M | 746.00M | 709.00M |
EBITDA | 3.18B | 3.64B | 3.87B | 3.79B | 3.28B |
EBITDA Ratio | 20.56% | 22.39% | 25.61% | 53.51% | 25.98% |
Operating Income | 2.51B | 2.68B | 2.92B | -979.00M | 1.85B |
Operating Income Ratio | 16.27% | 17.89% | 19.40% | -6.77% | 12.89% |
Total Other Income/Expenses | -322.00M | -38.00M | 5.00M | -37.00M | 274.00M |
Income Before Tax | 2.19B | 2.64B | 2.93B | -1.02B | 2.12B |
Income Before Tax Ratio | 14.18% | 17.64% | 19.43% | -7.02% | 14.80% |
Income Tax Expense | 526.00M | 550.00M | 894.00M | -137.00M | 685.00M |
Net Income | 1.66B | 2.06B | 2.08B | -879.00M | 1.44B |
Net Income Ratio | 10.77% | 13.81% | 13.80% | -6.08% | 10.02% |
EPS | 0.90 | 1.08 | 1.08 | -0.47 | 0.76 |
EPS Diluted | 0.87 | 1.08 | 1.08 | -0.47 | 0.76 |
Weighted Avg Shares Out | 1.85B | 1.91B | 1.89B | 1.89B | 1.89B |
Weighted Avg Shares Out (Dil) | 1.92B | 1.91B | 1.89B | 1.89B | 1.89B |
![News image](https://images.financialmodelingprep.com/news/like-passive-income-then-youll-love-these-3-super-20241204.jpg)
Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months.
![News image](https://images.financialmodelingprep.com/news/kenvue-lots-of-potential-but-shortterm-upside-may-be-20241127.jpg)
Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
![News image](https://images.financialmodelingprep.com/news/kenvue-announces-participation-in-the-morgan-stanley-global-consumer-retail-20241125.jpg)
Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference
![News image](https://images.financialmodelingprep.com/news/tylenol-maker-kenvue-hails-efficiency-gains-as-activist-starboard-20241107.jpg)
Tylenol maker Kenvue hails efficiency gains as activist Starboard watches on
![News image](https://images.financialmodelingprep.com/news/kenvue-inc-kvue-q3-2024-earnings-call-transcript-20241107.jpg)
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
![News image](https://images.financialmodelingprep.com/news/heres-what-key-metrics-tell-us-about-kenvue-kvue-20241107.jpg)
Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
![News image](https://images.financialmodelingprep.com/news/kenvue-kvue-q3-earnings-surpass-estimates-20241107.jpg)
Kenvue (KVUE) Q3 Earnings Surpass Estimates
![News image](https://images.financialmodelingprep.com/news/kenvue-misses-quarterly-sales-estimates-on-sluggish-skincare-sales-20241107.jpg)
Kenvue misses quarterly sales estimates on sluggish skincare sales
![News image](https://images.financialmodelingprep.com/news/kenvue-reports-third-quarter-2024-results-20241107.jpg)
Kenvue Reports Third Quarter 2024 Results
![News image](https://images.financialmodelingprep.com/news/stay-ahead-of-the-game-with-kenvue-kvue-q3-20241104.jpg)
Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics
Source: https://incomestatements.info
Category: Stock Reports